Skip to search formSkip to main contentSkip to account menu

SR 49059

Known as: SR-49059, SR49059 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

relcovaptan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Neuroanatomical distribution of oxytocin and vasopressin 1a receptors in the socially monogamous coppery titi monkey (Callicebus cupreus)
Highly Cited
2014
Highly Cited
2014
Body temperature and cardiac changes induced by peripherally administered oxytocin, vasopressin and the non‐peptide oxytocin receptor agonist WAY 267,464: a biotelemetry study in rats
There is current interest in oxytocin (OT) as a possible therapeutic in psychiatric disorders. However, the usefulness of OT may… 
Highly Cited
2013
Highly Cited
2013
Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia
Significance In this study, we show that a primitive brain hormone, arginine vasopressin (AVP), which has hitherto been… 
Highly Cited
2007
Highly Cited
2007
Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
Intracellular retention of a functional vasopressin V2 receptor (V2R) is a major cause of congenital nephrogenic diabetes… 
Highly Cited
2005
Highly Cited
2005
Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus.
In many mendelian diseases, some mutations result in the synthesis of misfolded proteins that cannot reach a transport-competent… 
Highly Cited
2004
Highly Cited
2004
Pharmacochaperones Post-translationally Enhance Cell Surface Expression by Increasing Conformational Stability of Wild-type and Mutant Vasopressin V2 Receptors*
Some membrane-permeable antagonists restore cell surface expression of misfolded receptors retained in the endoplasmic reticulum… 
Highly Cited
2004
Highly Cited
2004
Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059.
In most cases, nephrogenic diabetes insipidus results from mutations in the V2 vasopressin receptor (V2R) gene that cause… 
Highly Cited
2002
Highly Cited
2002
Effects of Nonpeptide V1 Vasopressin Receptor Antagonist SR-49059 on Infarction Volume and Recovery of Function in a Focal Embolic Stroke Model
Background and Purpose— Cerebral edema develops very early after the onset of focal cerebral ischemia and may be a major factor… 
Review
2002
Review
2002
Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
Highly Cited
2000
Highly Cited
2000
Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea
Objective To investigate the clinical effect of SR49059 when given shortly before the onset of menstruation as a preventative… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)